Areteia Therapeutics

Market position

Areteia targeted eosinophilic asthma, which the company said affects more than half of asthma patients out of more than a quarter of a billion people worldwide with asthma. It cited an asthma biologic market of roughly $8 billion growing about 10% per year, with IL-5 biologics representing approximately $3 billion, and positioned an oral eosinophil-lowering drug as a compelling alternative to injectable biologics.

Areteia positioned dexpramipexole as a first-in-class oral eosinophil maturation inhibitor and a potential first-to-market oral therapy for eosinophilic asthma, presented as an alternative to oral steroids and injected biologic treatments and potentially usable earlier in the asthma treatment paradigm. Supporting Phase 2 data cited by the company showed significant, dose-dependent reductions in blood absolute eosinophil count across tested doses versus placebo, with adverse events balanced across arms and no serious adverse events or discontinuations due to adverse events.

Technology

Dexpramipexole, an oral small molecule in Phase 3 development for eosinophilic asthma. Based on evidence from cell cultures and human biopsies, it inhibits the maturation and release of eosinophils in bone marrow, lowering peripheral blood eosinophil levels in a manner the company described as similar to injectable anti-IL-5 biologics. A Phase 2 study in moderate-to-severe eosinophilic asthma reported significant, dose-dependent reductions in blood absolute eosinophil count at 37.5 mg, 75 mg, and 150 mg twice-daily doses versus placebo.

Go-to-market

Pre-commercial. The company's plan was to advance dexpramipexole through Phase 3 clinical trials and secure commercial supply ahead of a potential launch, with leadership recruited from large-cap respiratory commercial organizations (its CEO previously led GlaxoSmithKline's US Respiratory Business Unit).

Patients with eosinophilic asthma, including those with moderate-to-severe or uncontrolled disease driven by elevated eosinophil levels, and the physicians treating them; the company framed its oral candidate as an alternative to oral steroids and injectable biologics.

Geography

Headquartered in Chapel Hill, North Carolina, US; the July 2022 launch announcement was datelined Pittsburgh, PA and Short Hills, NJ. The February 2024 financing was intended in part to add clinical development in Japan and several additional global markets. Post-shutdown correspondence is directed to an address in Foxboro, Massachusetts.

History

Areteia was created in 2022 by Population Health Partners and Knopp Biosciences and announced its launch on July 12, 2022, with a commitment of up to $350 million in Series A financing led by Bain Capital Life Sciences. Knopp contributed dexpramipexole and related assets to the new company, and Jorge Bartolome was appointed CEO at launch. In February 2024, Areteia raised an additional $75 million in Series A financing, bringing total Series A funding to $425 million, to expand the Phase III program into Japan and other global markets, expand manufacturing, and pursue life-cycle management including a once-daily formulation. As of the sources reviewed, the company's website states that Areteia is no longer operating, with inquiries about company assets directed to an outside contact and correspondence sent to an address in Foxboro, MA; Bain Capital Life Sciences lists Areteia's portfolio status as 'Former.'

Risks & controversies

The company ceased operations; its website states it is no longer operating and directs inquiries regarding company assets to an external contact, and its lead investor lists it as a former portfolio company. The sources reviewed do not state the reasons for the wind-down. Reporting on the company also contains inconsistencies: one aggregator lists the company as active with 10,000+ employees and names investors (e.g., Biomatics Capital Partners, Citi Ventures, Polaris Partners, Vertex Ventures) not corroborated by the company's own launch announcement or its lead investor's portfolio page, and another database describes 'Access Industries' where primary sources name 'Access Biotechnology.'